A new triple-receptor drug hit 28% weight loss in phase 3 — but full trial data aren't published yet
GLP-1 drugs are everywhere — in diabetes clinics, weight-loss offices, and now oncology wards, cardiology suites, and addiction medicine.
This week's research asks the harder questions: what happens when you stop taking them, who can't access them, and how far can the next generation go?
🔬 Retatrutide: Three receptors, 28% weight loss, and a lot of asterisks
- Retatrutide hits three metabolic receptors at once — the same two targeted by tirzepatide, plus a glucagon receptor — and phase 3 sponsor disclosures report mean weight reductions of 28.3% at 80 weeks and 28.7% at 68 weeks in obesity trials. Those numbers are striking. They're also provisional: only one phase 3 trial (in early type 2 diabetes) has a full peer-reviewed report. The obesity results are currently topline sponsor disclosures, not published trial data.
- The drug's molecular design is genuinely novel — a 39-amino-acid peptide engineered to balance incretin activity with glucagon receptor engagement while keeping blood sugar stable. But that glucagon component raises real questions about lean mass loss, heart rate changes, and gastrointestinal tolerability that the full data haven't yet resolved.
- The catch: estimands matter here. A "treatment-regimen" estimate from the same trial came in at 25% — still large, but a meaningful gap from the headline 28.3% figure, depending on how discontinuations are handled.
Why it matters: Retatrutide could represent a step-change in obesity pharmacology, but interpreting it responsibly requires waiting for the peer-reviewed trial reports.
Key Findings
💊 Tirzepatide edges semaglutide on gallstone risk in 242,000-patient study
- In a propensity-matched real-world comparison, semaglutide users had an 11% higher rate of gallstones and a 22% higher rate of gallbladder inflammation than tirzepatide users over one year.
- Both drugs still looked better than DPP-4 inhibitors across biliary and pancreatic outcomes — including a 32% lower rate of acute pancreatitis — so the headline isn't that GLP-1 drugs are risky; it's that they're not all identical.
🧠 GLP-1 drugs and cognition: the evidence is thinner than the headlines
- A meta-analysis of five randomized controlled trials covering 13,711 participants found no statistically significant effect of GLP-1 drugs on global cognition, attention, or other cognitive domains in adults at risk for Alzheimer's disease.
- Only four trials contributed usable data, and a sensitivity analysis removing the largest single trial left the pooled estimate imprecise and inconclusive. The researchers call current findings "exploratory and hypothesis-generating."
⚖️ Stopping GLP-1 drugs means the weight comes back — and so does the cardiometabolic risk
- A systematic review confirms what clinical intuition already suggested: weight regain and loss of cardiometabolic benefit are common after discontinuing GLP-1 or dual GLP-1/GIP drugs, and maintenance strategies remain poorly characterized.
- The finding reframes these medications less as courses of treatment and more as chronic therapies — which has direct implications for coverage decisions and how insurers approach prior authorization.
🏥 Insurance denials for GLP-1 drugs vary sharply by payer type
- A study tracking GLP-1 prescription denials across commercial, Medicare, and Medicaid coverage from 2018–2024 found that access remains strongly shaped by payer type and utilization management policies.
- A companion analysis of Medicaid data found that as of late 2024, only 13 states covered GLP-1 drugs for obesity, and prescriptions were heavily concentrated in those states — reaching 16.2 per 1,000 Medicaid beneficiaries in covered states by Q4 2024.
🍺 Semaglutide cut alcohol intake in rats — and eased withdrawal anxiety
- In alcohol-preferring rats, semaglutide reduced voluntary alcohol consumption in a dose-dependent manner and produced anxiolytic effects during withdrawal in an open-field test.
- The drug also reduced GABAergic signaling in a brain region linked to stress and emotional regulation. These are animal findings, and the jump to human alcohol use disorder treatment requires dedicated clinical trials — but the mechanistic signal is consistent with earlier work in this area.
🫀 GLP-1 drugs linked to lower cardiac death and stroke across 82,000-patient meta-analysis
- A meta-analysis of 12 randomized controlled trials found GLP-1 drugs associated with lower rates of cardiac death, all-cause mortality, stroke, and revascularization compared to placebo or standard care.
- The reductions in myocardial infarction and heart failure hospitalization did not reach statistical significance — so the cardiovascular benefit appears real but is not uniform across every cardiac endpoint.
Implications
The same week that retatrutide's provisional 28% weight-loss figure circulated widely, two separate analyses confirmed that access to existing GLP-1 drugs is still determined more by zip code and insurance type than by clinical need. The unresolved tension: if weight regain is near-universal after stopping, and coverage remains this fragmented, who actually benefits long-term?
Studies in this issue
Primary sources used for this newsletter.
- Retatrutide as a Single Drug Activating Three Hormone Receptors: Design, Development, and Review of New Phase 3 Resultsmain storyPharmaceutics2026-10-27PMID 42942810
- Effects of GLP-1 Receptor Drugs on Thinking Skills in Adults at Risk for Alzheimer's Diseasekey findingNutrients2026-10-27PMID 42942883
- Prescription denials for diabetes and weight-loss drugs under commercial, Medicare, and Medicaid plans from 2018 to 2024key findingHealth affairs scholar2026-10-28PMID 42948647
- Glucagon-like-peptide-1 receptor agonists and their impact on major heart and blood vessel health outcomeskey findingMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace2026-10-28PMID 42948977
- Weight gain after stopping GLP-1 and GIP/GLP-1 hormone treatments: A systematic reviewkey findingMetabolites2026-10-27PMID 42941232
- Bile Duct and Pancreas Safety of Incretin-Based Treatments in Obesity and Type 2 Diabetes Compared Between Tirzepatide, Semaglutide, and DPP-4 Inhibitorskey findingJournal of clinical medicine2026-10-27PMID 42941539
- Semaglutide lowers alcohol drinking and anxiety-like behavior during withdrawal in alcohol-preferring ratskey findingNeuropharmacology2026-10-27PMID 42946204
Continue reading
All GLP-1 Therapies issuesGet the next GLP-1 Therapies issue
Seven papers, once a week. Free.